Tenax Therapeutics, Inc.(TENX)Earnings, Financials & Key Ratios
TENX•NASDAQ
$12.02
$71M mkt cap·Price updated May 6, 2026
AboutTenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.Show more
- Revenue$0
- EBITDA-$18M-113.7%
- Net Income-$18M-128.3%
- EPS (Diluted)-1.15+96.3%
- ROE-35.17%+78.1%
- Interest Coverage-847.57-146.7%
TENX Key Insights
Tenax Therapeutics, Inc. (TENX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 87 (top 13%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TENX Price & Volume
Tenax Therapeutics, Inc. (TENX) stock price & volume — 10-year historical chart
Loading chart...
TENX Growth Metrics
Tenax Therapeutics, Inc. (TENX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-197.57%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM92.92%
Return on Capital
10 Years-191.29%
5 Years-304.4%
3 Years-192.95%
Last Year-38.95%
TENX Peer Comparison
Tenax Therapeutics, Inc. (TENX) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ATHA | 17.12M | 4.34 | -0.17 | -340.97% | 0.03 | |||
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 PRTA | 601.85M | 11.18 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 MDGL | 12.38B | 539.73 | -42.00 | 432.05% | -27.32% | -50.15% | 0.59 | |
 ESPR | 753.05M | 3.15 | -28.64 | 21.31% | -5.63% | |||
 RCKT | 418.11M | 3.86 | -1.92 | -80.49% | 0.09 |
Compare TENX vs Peers
Tenax Therapeutics, Inc. (TENX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TENX Income Statement
Tenax Therapeutics, Inc. (TENX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -100% | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 18.95K | 13.62K | 9.02K | 0 | 114.75K | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -18.95K▲ 0% | -13.62K▲ 28.1% | -9.02K▲ 33.8% | 0▲ 100.0% | -114.75K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -147.91% | 28.13% | 33.82% | 100% | - | 100% | - | - | - | - |
| Operating Expenses | 52.65M | 9.21M | 6.89M | 8.56M | 9.75M | 32.73M | 11.05M | 8.23M | 19.49M | 47.23M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 6.25M | 5.68M | 5.65M | 5.08M | 5.19M | 7.58M | 5.68M | 5M | 6.79M | 20.51M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 35.14M | 3.53M | 1.24M | 3.47M | 4.56M | 25.15M | 5.38M | 3.23M | 12.71M | 26.73M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 33.27M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -52.65M▲ 0% | -9.21M▲ 82.5% | -6.89M▲ 25.1% | -8.56M▼ 24.1% | -9.87M▼ 15.3% | -32.73M▼ 231.7% | -11.05M▲ 66.2% | -8.23M▲ 25.5% | -19.49M▼ 136.8% | -47.23M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -236.68% | 82.52% | 25.12% | -24.11% | -15.34% | -231.66% | 66.23% | 25.5% | -136.75% | - |
| EBITDA | -52.63M | -9.19M | -6.88M | -8.55M | -9.75M | -32.62M | -10.94M | -8.23M | -17.58M | -43.33M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -237.57% | 82.53% | 25.11% | -24.2% | -14.07% | -234.45% | 66.46% | 24.8% | -113.7% | -195.79% |
| D&A (Non-Cash Add-back) | 18.95K | 13.62K | 9.02K | 5.02K | 114.75K | 108.98K | 113.33K | 8K | 0 | 0 |
| EBIT | -51.89M | -9.21M | -6.89M | -8.56M | -9.85M | -32.47M | -11.04M | -7.69M | -17.58M | -43.33M |
| Net Interest Income | 0 | 0 | 0 | 144K | 29.37K | -949 | -4.44K | -23.97K | 1.89M | 3.93M |
| Interest Income | 0 | 0 | 0 | 144K | 31K | 0 | 0 | 0 | 1.91M | 3.93M |
| Interest Expense | 32.5M | 0 | 0 | 0 | 1.63K | 949 | 4.44K | 23.97K | 23K | 0 |
| Other Income/Expense | 764.74K | 366.22K | 79.83K | 160.9K | 16.54K | 253.88K | 4.75K | 523K | 1.89M | 3.9M |
| Pretax Income | -51.89M▲ 0% | -8.84M▲ 83.0% | -6.81M▲ 22.9% | -8.39M▼ 23.2% | -9.85M▼ 17.4% | -32.47M▼ 229.6% | -11.05M▲ 66.0% | -7.71M▲ 30.2% | -17.6M▼ 128.3% | -43.33M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | -7.96M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 15.35% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -43.92M▲ 0% | -8.84M▲ 79.9% | -6.81M▲ 22.9% | -8.39M▼ 23.2% | -9.85M▼ 17.4% | -32.47M▼ 229.6% | -11.05M▲ 66.0% | -7.71M▲ 30.2% | -17.6M▼ 128.3% | -43.33M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -211.92% | 79.88% | 22.92% | -23.2% | -17.36% | -229.64% | 65.98% | 30.2% | -128.27% | -197.57% |
| Net Income (Continuing) | -43.92M | -8.84M | -6.81M | -8.39M | -9.85M | -32.47M | -11.05M | -7.71M | -17.6M | -43.33M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -624.82▲ 0% | -10022.32▼ 1504.0% | -7359.14▲ 26.6% | -26.60▲ 99.6% | -2125.38▼ 7890.2% | -2524.80▼ 18.8% | -600.80▲ 76.2% | -31.04▲ 94.8% | -1.15▲ 96.3% | -1.09▲ 0% |
| EPS Growth % | -211.46% | -1504.03% | 26.57% | 99.64% | -7890.15% | -18.79% | 76.2% | 94.83% | 96.3% | 92.92% |
| EPS (Basic) | -624.82 | -10022.32 | -7359.14 | -26.60 | -2125.38 | -2524.80 | -600.80 | -31.09 | -1.15 | - |
| Diluted Shares Outstanding | 879 | 1.41M | 915 | 3.87K | 4.63K | 12.86K | 18.39K | 248.45K | 15.27M | 39.74M |
| Basic Shares Outstanding | 879 | 1.41M | 915 | 3.87K | 4.63K | 12.86K | 18.39K | 248K | 15.27M | 39.74M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TENX Balance Sheet
Tenax Therapeutics, Inc. (TENX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 13.63M | 8.06M | 13.32M | 6.18M | 6.8M | 5.69M | 3.21M | 11.68M | 96.69M | 102.81M |
| Cash & Short-Term Investments | 13.28M | 7.73M | 12.86M | 5.4M | 6.71M | 5.58M | 2.12M | 9.79M | 94.85M | 99.37M |
| Cash Only | 10M | 1.6M | 12.37M | 4.91M | 6.25M | 5.58M | 2.12M | 9.79M | 94.85M | 99.37M |
| Short-Term Investments | 3.28M | 6.12M | 494.63K | 493.88K | 462.69K | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 72.6K | 50.17K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 345.86K | 251.58K | 64K | 3.44M |
| Total Non-Current Assets | 9.71M | 1.83M | 16.96K | 184.44K | 73.19K | 303.24K | 196.24K | 1.12K | 0 | 0 |
| Property, Plant & Equipment | 19.11K | 9.95K | 8.53K | 176.01K | 64.75K | 294.8K | 186.69K | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 8.59M | 1.81M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.11M | 8.44K | 8.44K | 8.44K | 8.44K | 8.44K | 9.55K | 1.12K | 0 | 0 |
| Total Assets | 23.34M▲ 0% | 9.89M▼ 57.6% | 13.34M▲ 34.8% | 6.37M▼ 52.3% | 6.87M▲ 7.9% | 5.99M▼ 12.8% | 3.4M▼ 43.2% | 11.68M▲ 243.2% | 96.69M▲ 727.5% | 102.81M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | -68.02% | -57.62% | 34.85% | -52.27% | 7.91% | -12.76% | -43.18% | 243.19% | 727.46% | 2302.5% |
| Total Current Liabilities | 6.2M | 1.01M | 1.57M | 2.53M | 2.12M | 1.56M | 1.85M | 3.59M | 4.69M | 6.6M |
| Accounts Payable | 727.6K | 611.86K | 749.81K | 1.66M | 757.86K | 859.64K | 448.43K | 2.07M | 3.16M | 5.61M |
| Days Payables Outstanding | 14.01K | 16.4K | 30.36K | - | 2.41K | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 120.49K | 0 | 624.3K | 500.9K | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 226.09K | 33.67K | 244.46K | 426.12K | 319.61K | 0 | 245.39K | 236.88K | 0 | 991K |
| Current Ratio | 2.20x | 7.99x | 8.51x | 2.44x | 3.21x | 3.64x | 1.74x | 3.26x | 20.60x | 20.60x |
| Quick Ratio | 2.20x | 7.99x | 8.51x | 2.44x | 3.21x | 3.64x | 1.74x | 3.26x | 20.60x | 20.60x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 60.38K | 124.17K | 183.59K | 64.2K | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 124.17K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 60.38K | 0 | 183.59K | 64.2K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 6.2M | 1.01M | 1.57M | 2.59M | 2.24M | 1.75M | 1.91M | 3.59M | 4.69M | 6.6M |
| Total Debt | 0 | 0 | 0 | 171.73K | 305.04K | 290.78K | 807.89K | 500.9K | 0 | 0 |
| Net Debt | -10M | -1.6M | -12.37M | -4.73M | -5.95M | -5.29M | -1.32M | -9.29M | -94.85M | -99.37M |
| Debt / Equity | - | - | - | 0.05x | 0.07x | 0.07x | 0.54x | 0.06x | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 2.29x |
| Interest Coverage | -1.62x | - | - | - | -6065.11x | -34487.08x | -2487.65x | -343.56x | -847.57x | - |
| Total Equity | 17.14M▲ 0% | 8.88M▼ 48.2% | 11.77M▲ 32.5% | 3.77M▼ 68.0% | 4.63M▲ 22.6% | 4.24M▼ 8.2% | 1.49M▼ 64.8% | 8.1M▲ 442.5% | 91.99M▲ 1036.0% | 96.21M▲ 0% |
| Equity Growth % | -71.63% | -48.18% | 32.53% | -67.95% | 22.61% | -8.23% | -64.83% | 442.5% | 1035.98% | 2878.36% |
| Book Value per Share | 19506.16 | 6.30 | 12865.06 | 974.30 | 997.96 | 330.07 | 81.17 | 32.59 | 6.02 | 2.42 |
| Total Shareholders' Equity | 17.14M | 8.88M | 11.77M | 3.77M | 4.63M | 4.24M | 1.49M | 8.1M | 91.99M | 96.21M |
| Common Stock | 2.81K | 141 | 379 | 674 | 1.26K | 2.52K | 4.58K | 30 | 0 | 1K |
| Retained Earnings | -204.66M | -213.5M | -227.8M | -236.17M | -246.02M | -278.49M | -289.54M | -297.25M | -314.86M | -351.91M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -18.72K | -16.19K | 516 | 458 | -70 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TENX Cash Flow Statement
Tenax Therapeutics, Inc. (TENX) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -15.87M | -12.14M | -5.5M | -7.56M | -9.27M | -10.86M | -12.01M | -5.9M | -14.81M | -14.81M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -62.8% | 23.51% | 54.7% | -37.4% | -22.72% | -17.08% | -10.65% | 50.85% | -150.86% | -538.32% |
| Net Income | -43.92M | -8.84M | -14.14M | -8.39M | -9.85M | -32.47M | -11.05M | -7.71M | -17.6M | -43.33M |
| Depreciation & Amortization | 18.95K | 13.62K | 9.02K | 107.28K | 114.75K | 108.98K | 113.33K | 8K | 0 | 0 |
| Stock-Based Compensation | 1.06K | 79.59K | 190.08K | 0 | 0 | 0 | 0 | 191K | 1.13M | 0 |
| Deferred Taxes | -7.96M | -4.83K | 407.77K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 34.08M | 498.49K | 7.43M | 270.51K | 361.34K | 22.12M | 366.86K | 25K | 23K | 15.34M |
| Working Capital Changes | 1.92M | -3.89M | 606.75K | 460.4K | 102.44K | -610.09K | -1.45M | 1.58M | 1.64M | 2.07M |
| Change in Receivables | 23.8K | 1.11M | -122.61K | 0 | 698.37K | -22.5K | 0 | -306K | 58K | 0 |
| Change in Inventory | -2.72M | 5M | -729.36K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 2.72M | -5M | 729.36K | 883.04K | 0 | 0 | -344.95K | 1.65M | 1.06M | 4.06M |
| Cash from Investing | 22.21M | 3.75M | 7.35M | -1.65K | 20.11K | 452.61K | -2.32K | 3K | 0 | 0 |
| Capital Expenditures | -2.88K | -4.54K | -7.59K | -3.57K | -3.49K | -5.25K | -2.32K | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 75K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 75K | 3.75K | 7.36K | 0 | 0 | 0 | 0 | 3K | 0 | 0 |
| Cash from Financing | 280.59K | 498.49K | 8.91M | 96.5K | 10.6M | 9.74M | 8.55M | 13.57M | 99.87M | 26.97M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 244.66K | 0 | 624.3K | -624K | -501K | -97 |
| Equity Issued (Net) | 0 | 0 | 0 | 96.5K | 1000K | 1000K | 1000K | 0 | 0 | 2.35M |
| Dividends Paid | 0 | 0 | -7.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -489.32K | -498.49K | 16.24M | 0 | 1.69M | 544.65K | 0 | 14.19M | 100.37M | 0 |
| Net Change in Cash | 6.34M▲ 0% | -8.39M▼ 232.4% | 10.76M▲ 228.3% | -7.46M▼ 169.3% | 1.34M▲ 118.0% | -666.32K▼ 149.6% | -3.46M▼ 419.3% | 7.67M▲ 321.6% | 85.06M▲ 1009.3% | 1.06M▲ 0% |
| Free Cash Flow | -15.87M▲ 0% | -12.15M▲ 23.5% | -5.51M▲ 54.7% | -7.56M▼ 37.3% | -9.28M▼ 22.7% | -10.86M▼ 17.1% | -12.02M▼ 10.6% | -5.9M▲ 50.9% | -14.81M▼ 150.9% | -25.91M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -61.02% | 23.49% | 54.66% | -37.27% | -22.71% | -17.09% | -10.62% | 50.86% | -150.86% | -107.98% |
| FCF per Share | -18064.61 | -8.61 | -6018.64 | -1952.41 | -2001.37 | -844.59 | -653.32 | -23.76 | -0.97 | -0.97 |
| FCF Conversion (FCF/Net Income) | 0.36x | 1.37x | 0.81x | 0.90x | 0.94x | 0.33x | 1.09x | 0.77x | 0.84x | 0.60x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24K | 23K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TENX Key Ratios
Tenax Therapeutics, Inc. (TENX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -113.26% | -67.94% | -65.98% | -108.01% | -234.61% | -732.21% | -385.12% | -160.8% | -35.17% | -45.03% |
| Return on Invested Capital (ROIC) | -123.38% | -95.75% | -154.76% | - | - | - | - | - | - | 1375.12% |
| Debt / Equity | - | - | - | 0.05x | 0.07x | 0.07x | 0.54x | 0.06x | - | 0.00x |
| Interest Coverage | -1.62x | - | - | - | -6065.11x | -34487.08x | -2487.65x | -343.56x | -847.57x | - |
| FCF Conversion | 0.36x | 1.37x | 0.81x | 0.90x | 0.94x | 0.33x | 1.09x | 0.77x | 0.84x | 0.60x |
| Revenue Growth | -100% | - | - | - | - | - | - | - | - | - |
TENX Frequently Asked Questions
Tenax Therapeutics, Inc. (TENX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tenax Therapeutics, Inc. (TENX) grew revenue by 0.0% over the past year. Growth has been modest.
Tenax Therapeutics, Inc. (TENX) reported a net loss of $43.3M for fiscal year 2024.
Dividend & Returns
Tenax Therapeutics, Inc. (TENX) has a return on equity (ROE) of -35.2%. Negative ROE indicates the company is unprofitable.
Tenax Therapeutics, Inc. (TENX) had negative free cash flow of $25.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More TENX
Tenax Therapeutics, Inc. (TENX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates